AKT-I-1
Code | Size | Price |
---|
TAR-T25017-1mg | 1mg | £258.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T25017-5mg | 5mg | £454.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T25017-10mg | 10mg | £631.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T25017-25mg | 25mg | £946.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T25017-50mg | 50mg | £1,251.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T25017-100mg | 100mg | £1,669.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
AKT-I-1 is a selective and reversible inhibitor of Akt1.
CAS:
473382-39-7
Formula:
C22H30N6
Molecular Weight:
378.524
Pathway:
PI3K/Akt/mTOR signaling; Cytoskeletal Signaling
Purity:
0.98
SMILES:
CN(C)CC(C)(C)CNc1nn2c(nnc2cc1C1CCC1)-c1ccccc1
Target:
Akt
References
1. Zhang Q, et al. Autophagy prevention sensitizes AKTi-1/2-induced anti-hepatocellular carcinoma cell activity in vitro and in vivo. Biochem Biophys Res Commun. 2016 Nov 18;480(3):334-340.
2. Zhao QW, et al. Akt mediated phosphorylation of Oct4 is associated with the proliferation of stem like cancer cells. Oncol Rep. 2015 Apr;33(4):1621-9.
3. Yamaji M, et al. Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells. Cancer Med. 2017 Nov;6(11):2646-2659.
4. Liebl D, et al. SopB-Mediated Recruitment of SNX18 Facilitates Salmonella Typhimurium Internalization by the Host Cell. Front Cell Infect Microbiol. 2017 Jun 15;7:257.